Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Update

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 109,200 shares, an increase of 30.5% from the December 15th total of 83,700 shares. Based on an average daily volume of 625,300 shares, the short-interest ratio is presently 0.2 days. Currently, 0.7% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Sensei Biotherapeutics in a research report on Wednesday, January 8th.

Sensei Biotherapeutics Trading Up 2.4 %

NASDAQ:SNSE traded up $0.01 during trading hours on Friday, hitting $0.52. 160,890 shares of the stock were exchanged, compared to its average volume of 1,146,721. The company has a market cap of $13.10 million, a P/E ratio of -0.44 and a beta of 0.17. The firm’s fifty day moving average price is $0.50 and its 200 day moving average price is $0.55. Sensei Biotherapeutics has a 52-week low of $0.38 and a 52-week high of $1.94.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. National Bank of Canada FI lifted its stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 45,575 shares of the company’s stock after purchasing an additional 35,575 shares during the period. National Bank of Canada FI owned 0.18% of Sensei Biotherapeutics worth $27,000 as of its most recent SEC filing. 10.50% of the stock is owned by institutional investors and hedge funds.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.